Last 34 quarters of trend data · Healthcare · Neuroscience Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -43.92 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 11.35 | 9.08 | 10.09 | 9.94 | 7.00 | 3.59 | 7.44 | 4.38 | 5.72 | 4.55 | 4.75 | 1.61 | 2.42 | 2.48 | 1.79 | 1.76 | 0.97 | 2.76 | 6.48 | 0.99 | 2.66 |
| — | +152.9% | +35.7% | +126.8% | +22.2% | -21.1% | +56.7% | +171.4% | +136.8% | +83.4% | +164.7% | -8.4% | +150.3% | -10.3% | -72.3% | +78.1% | -63.7% | +8.3% | +191.6% | -39.8% | +29.6% | |
| P/FCF | — | — | — | 77.90 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -30.2% | -7.2% | -7.4% | -4.5% | -6.1% | -8.3% | -10.4% | -14.4% | -21.2% | -17.8% | -14.1% | -9.1% | -8.3% | -7.3% | -6.1% | -5.1% | -9.7% | -22.7% | -53.2% | -59.9% | -49.8% |
| — | +12.7% | +28.5% | +69.0% | +71.3% | +53.7% | +26.2% | -58.4% | -153.9% | -145.6% | -130.0% | -79.4% | +14.1% | +68.0% | +88.5% | +91.5% | +80.5% | +52.0% | -62.0% | -97.8% | -155.5% | |
| ROA | -28.1% | -7.0% | -7.1% | -4.2% | -5.8% | -7.8% | -9.5% | -12.7% | -18.6% | -16.2% | -13.0% | -8.4% | -7.8% | -6.6% | -5.4% | -4.4% | -7.9% | -14.4% | -21.3% | -24.3% | -20.5% |
| — | +10.6% | +25.5% | +66.7% | +68.8% | +51.9% | +26.9% | -50.4% | -137.3% | -146.4% | -142.6% | -92.7% | +0.8% | +54.3% | +74.9% | +82.0% | +61.6% | +39.7% | -14.4% | -31.5% | -43.0% | |
| ROIC | -31.9% | -7.3% | -7.0% | -5.1% | -9.7% | -12.6% | -11.7% | -16.6% | -21.5% | -17.5% | -16.0% | -11.5% | -9.2% | -6.9% | -5.6% | -6.3% | -12.3% | -26.7% | — | — | — |
| — | +42.0% | +39.7% | +69.1% | +55.0% | +27.8% | +27.4% | -44.4% | -133.9% | -152.5% | -187.4% | -82.2% | +25.4% | +74.1% | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.09 | 0.09 | 0.10 | 0.21 | 1.36 | 0.86 | 1.27 |
| — | -58.1% | -58.8% | -60.3% | -77.0% | -75.1% | -45.2% | -36.1% | +20.4% | +16.6% | -80.2% | -81.0% | -84.1% | -92.5% | -93.5% | -90.0% | -92.2% | -74.6% | +122.3% | +64.5% | +222.3% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 19.66 | 37.28 | 24.75 | 19.66 | 21.93 | 22.42 | 15.38 | 10.41 | 7.38 | 10.68 | 14.55 | 15.03 | 18.16 | 21.06 | 8.65 | 9.15 | 8.70 | 5.18 | 2.32 | 2.98 | 3.10 |
| — | +66.3% | +60.9% | +88.8% | +197.2% | +109.9% | +5.7% | -30.7% | -59.4% | -49.3% | +68.2% | +64.3% | +108.9% | +306.9% | +273.0% | +206.7% | +180.7% | +26.6% | -70.6% | -64.2% | -65.8% | |
| Quick Ratio | 19.66 | 37.28 | 24.75 | 19.66 | 21.93 | 22.42 | 15.38 | 10.41 | 7.38 | 10.68 | 14.55 | 15.03 | 18.16 | 21.06 | 8.65 | 9.15 | 8.70 | 5.18 | 2.32 | 2.98 | 3.10 |
| — | +66.3% | +60.9% | +88.8% | +197.2% | +109.9% | +5.7% | -30.7% | -59.4% | -49.3% | +68.2% | +64.3% | +108.9% | +306.9% | +273.0% | +206.7% | +180.7% | +26.6% | -70.6% | -64.2% | -65.8% | |
| Interest Coverage | — | — | — | — | — | — | — | -11398.00 | -13272.00 | -12359.00 | -10909.00 | -1949.75 | -2569.33 | -46.50 | -26.74 | -19.16 | -27.33 | -26.31 | -23.28 | -26.59 | -22.94 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 34 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TRVI stock.
Trevi Therapeutics, Inc.'s current P/E is -43.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Trevi Therapeutics, Inc.'s business trajectory between earnings reports.